Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Stock Down 1.1%

NASDAQ AVIR opened at $3.22 on Tuesday. The firm has a 50-day moving average price of $3.15 and a two-hundred day moving average price of $3.22. Atea Pharmaceuticals has a 12-month low of $2.45 and a 12-month high of $4.02. The company has a market capitalization of $255.14 million, a P/E ratio of -2.00 and a beta of 0.23.

Analyst Ratings Changes

Several brokerages recently issued reports on AVIR. Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen downgraded Atea Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its stake in Atea Pharmaceuticals by 80.4% during the first quarter. Jane Street Group LLC now owns 102,607 shares of the company’s stock worth $307,000 after purchasing an additional 45,716 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Atea Pharmaceuticals by 2.6% during the 2nd quarter. Rhumbline Advisers now owns 119,420 shares of the company’s stock worth $430,000 after buying an additional 2,977 shares during the last quarter. American Century Companies Inc. grew its position in Atea Pharmaceuticals by 6.7% in the second quarter. American Century Companies Inc. now owns 173,791 shares of the company’s stock valued at $626,000 after acquiring an additional 10,930 shares during the last quarter. Prudential Financial Inc. acquired a new position in Atea Pharmaceuticals during the second quarter worth about $36,000. Finally, Walleye Capital LLC bought a new position in shares of Atea Pharmaceuticals in the second quarter worth about $208,000. 86.67% of the stock is owned by institutional investors.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.